TABLE 4.
Subgroup Analysis of Clinical Outcomes a
| Outcome | 25 mg CBD (n = 16) | 50 mg CBD (n = 26) | Control (n = 40) | P |
|---|---|---|---|---|
| VAS pain | 0.7 ± 1.4 | 0.9 ± 1.8 | 1.2 ± 1.8 | .63 |
| ASES | 93.4 ± 11.2 | 92.1 ± 15.8 | 91.1 ± 15.0 | .75 |
| Activities of daily living | 46.6 ± 5.3 | 45.2 ± 8.6 | 46.2 ± 5.7 | .75 |
| Achieved PASS | 13 (83.3) | 21 (80.8) | 31 (77.5) | .93 |
| SANE | 87.3 ± 13.1 | 87.8 ± 11.9 | 90.1 ± 13.1 | .66 |
| VAS satisfaction | 97.6 ± 4.4 | 97.2 ± 5.7 | 95.4 ± 9.9 | .58 |
| Surgery met expectations | 16 (100) | 26 (100) | 39 (97.5) | .60 |
| Willing to repeat | 16 (100) | 24 (92.3) | 39 (97.5) | .15 |
a
Data reported as mean ± SD or n (%). ASES, American Shoulder and Elbow Surgeons Shoulder Score; CBD, cannabidiol, PASS, Patient Acceptable Symptom State; SANE, single assessment numeric evaluation; VAS visual analogue scale.